1	Potent	potent	_	_	_	_	_	_	_
2	and	and	_	_	_	_	_	_	_
3	stable	stable	_	_	_	_	_	_	_
4	attenuation	attenuation	_	_	_	_	_	_	_
5	of	of	_	_	_	_	_	_	_
6	live-HIV-1	live-hiv-1	_	_	_	_	_	_	_
7	by	by	_	_	_	_	_	_	_
8	gain	gain	_	_	_	_	_	_	_
9	of	of	_	_	_	_	_	_	_
10	a	a	_	_	_	_	_	_	_
11	proteolysis-resistant	proteolysis-resistant	_	_	_	_	_	_	_
12	inhibitor	inhibitor	_	_	_	_	_	_	_
13	of	of	_	_	_	_	_	_	_
14	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
15	(	(	_	_	_	_	_	_	_
16	IkappaB-alphaS32/36A	IkappaB-alphaS32/36A	_	_	_	_	_	_	_
17	)	)	_	_	_	_	_	_	_
18	and	and	_	_	_	_	_	_	_
19	the	the	_	_	_	_	_	_	_
20	implications	implication	_	_	_	_	_	_	_
21	for	for	_	_	_	_	_	_	_
22	vaccine	vaccine	_	_	_	_	_	_	_
23	development	development	_	_	_	_	_	_	_
24	.	.	_	_	_	_	_	_	_

1	Live-attenuated	live-attenuated	_	_	_	_	_	_	_
2	human	human	_	_	_	_	_	_	_
3	immunodeficiency	immunodeficiency	_	_	_	_	_	_	_
4	viruses	virus	_	_	_	_	_	_	_
5	(	(	_	_	_	_	_	_	_
6	HIVs	HIV	_	_	_	_	_	_	_
7	)	)	_	_	_	_	_	_	_
8	are	be	_	_	_	_	_	_	_
9	candidates	candidate	_	_	_	_	_	_	_
10	for	for	_	_	_	_	_	_	_
11	Acquired	acquire	_	_	_	_	_	_	_
12	Immunodeficiency	Immunodeficiency	_	_	_	_	_	_	_
13	Syndrome	Syndrome	_	_	_	_	_	_	_
14	(	(	_	_	_	_	_	_	_
15	AIDS	AIDS	_	_	_	_	_	_	_
16	)	)	_	_	_	_	_	_	_
17	vaccine	vaccine	_	_	_	_	_	_	_
18	.	.	_	_	_	_	_	_	_

1	Based	base	_	_	_	_	_	_	_
2	on	on	_	_	_	_	_	_	_
3	the	the	_	_	_	_	_	_	_
4	simian	simian	_	_	_	_	_	_	_
5	immunodeficiency	immunodeficiency	_	_	_	_	_	_	_
6	virus	virus	_	_	_	_	_	_	_
7	(	(	_	_	_	_	_	_	_
8	SIV	SIV	_	_	_	_	_	_	_
9	)	)	_	_	_	_	_	_	_
10	model	model	_	_	_	_	_	_	_
11	for	for	_	_	_	_	_	_	_
12	AIDS	AIDS	_	_	_	_	_	_	_
13	,	,	_	_	_	_	_	_	_
14	loss-of-function	loss-of-function	_	_	_	_	_	_	_
15	(	(	_	_	_	_	_	_	_
16	e.g.	e.g.	_	_	_	_	_	_	_
17	deletion	deletion	_	_	_	_	_	_	_
18	of	of	_	_	_	_	_	_	_
19	accessory	accessory	_	_	_	_	_	_	_
20	genes	gene	_	_	_	_	_	_	_
21	such	such	_	_	_	_	_	_	_
22	as	as	_	_	_	_	_	_	_
23	nef	nef	_	_	_	_	_	_	_
24	)	)	_	_	_	_	_	_	_
25	has	have	_	_	_	_	_	_	_
26	been	be	_	_	_	_	_	_	_
27	forwarded	forward	_	_	_	_	_	_	_
28	as	as	_	_	_	_	_	_	_
29	a	a	_	_	_	_	_	_	_
30	primary	primary	_	_	_	_	_	_	_
31	approach	approach	_	_	_	_	_	_	_
32	for	for	_	_	_	_	_	_	_
33	creating	create	_	_	_	_	_	_	_
34	enfeebled	enfeeble	_	_	_	_	_	_	_
35	,	,	_	_	_	_	_	_	_
36	but	but	_	_	_	_	_	_	_
37	replication-competent	replication-competent	_	_	_	_	_	_	_
38	,	,	_	_	_	_	_	_	_
39	HIV-1/SIV	HIV-1/SIV	_	_	_	_	_	_	_
40	.	.	_	_	_	_	_	_	_

1	Regrettably	regrettably	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	recent	recent	_	_	_	_	_	_	_
4	evidence	evidence	_	_	_	_	_	_	_
5	suggests	suggest	_	_	_	_	_	_	_
6	that	that	_	_	_	_	_	_	_
7	loss-of-function	loss-of-function	_	_	_	_	_	_	_
8	alone	alone	_	_	_	_	_	_	_
9	is	be	_	_	_	_	_	_	_
10	not	not	_	_	_	_	_	_	_
11	always	always	_	_	_	_	_	_	_
12	sufficient	sufficient	_	_	_	_	_	_	_
13	to	to	_	_	_	_	_	_	_
14	prevent	prevent	_	_	_	_	_	_	_
15	the	the	_	_	_	_	_	_	_
16	emergence	emergence	_	_	_	_	_	_	_
17	of	of	_	_	_	_	_	_	_
18	virulent	virulent	_	_	_	_	_	_	_
19	mutants	mutant	_	_	_	_	_	_	_
20	.	.	_	_	_	_	_	_	_

1	New	new	_	_	_	_	_	_	_
2	strategies	strategy	_	_	_	_	_	_	_
3	that	that	_	_	_	_	_	_	_
4	attenuate	attenuate	_	_	_	_	_	_	_
5	via	via	_	_	_	_	_	_	_
6	mechanisms	mechanism	_	_	_	_	_	_	_
7	distinct	distinct	_	_	_	_	_	_	_
8	from	from	_	_	_	_	_	_	_
9	loss-of-function	loss-of-function	_	_	_	_	_	_	_
10	are	be	_	_	_	_	_	_	_
11	needed	need	_	_	_	_	_	_	_
12	for	for	_	_	_	_	_	_	_
13	enhancing	enhance	_	_	_	_	_	_	_
14	the	the	_	_	_	_	_	_	_
15	safety	safety	_	_	_	_	_	_	_
16	phenotype	phenotype	_	_	_	_	_	_	_
17	of	of	_	_	_	_	_	_	_
18	viral	viral	_	_	_	_	_	_	_
19	genome	genome	_	_	_	_	_	_	_
20	.	.	_	_	_	_	_	_	_

1	Here	here	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	we	we	_	_	_	_	_	_	_
4	propose	propose	_	_	_	_	_	_	_
5	gain-of-function	gain-of-function	_	_	_	_	_	_	_
6	to	to	_	_	_	_	_	_	_
7	be	be	_	_	_	_	_	_	_
8	used	use	_	_	_	_	_	_	_
9	simultaneously	simultaneously	_	_	_	_	_	_	_
10	with	with	_	_	_	_	_	_	_
11	loss-of-function	loss-of-function	_	_	_	_	_	_	_
12	as	as	_	_	_	_	_	_	_
13	a	a	_	_	_	_	_	_	_
14	novel	novel	_	_	_	_	_	_	_
15	approach	approach	_	_	_	_	_	_	_
16	for	for	_	_	_	_	_	_	_
17	attenuating	attenuate	_	_	_	_	_	_	_
18	HIV-1	HIV-1	_	_	_	_	_	_	_
19	.	.	_	_	_	_	_	_	_

1	We	we	_	_	_	_	_	_	_
2	have	have	_	_	_	_	_	_	_
3	constructed	construct	_	_	_	_	_	_	_
4	an	an	_	_	_	_	_	_	_
5	HIV-1	HIV-1	_	_	_	_	_	_	_
6	genome	genome	_	_	_	_	_	_	_
7	carrying	carry	_	_	_	_	_	_	_
8	the	the	_	_	_	_	_	_	_
9	cDNA	cdna	_	_	_	_	_	_	_
10	of	of	_	_	_	_	_	_	_
11	a	a	_	_	_	_	_	_	_
12	proteolysis-resistant	proteolysis-resistant	_	_	_	_	_	_	_
13	nuclear	nuclear	_	_	_	_	_	_	_
14	factor-kappaB	factor-kappab	_	_	_	_	_	_	_
15	inhibitor	inhibitor	_	_	_	_	_	_	_
16	(	(	_	_	_	_	_	_	_
17	IkappaB-alphaS32/36A	IkappaB-alphaS32/36A	_	_	_	_	_	_	_
18	)	)	_	_	_	_	_	_	_
19	in	in	_	_	_	_	_	_	_
20	the	the	_	_	_	_	_	_	_
21	nef	nef	_	_	_	_	_	_	_
22	region	region	_	_	_	_	_	_	_
23	.	.	_	_	_	_	_	_	_

1	HIV-1	HIV-1	_	_	_	_	_	_	_
2	expressing	express	_	_	_	_	_	_	_
3	IkappaB-alphaS32/36A	IkappaB-alphaS32/36A	_	_	_	_	_	_	_
4	down-regulates	down-regulate	_	_	_	_	_	_	_
5	viral	viral	_	_	_	_	_	_	_
6	expression	expression	_	_	_	_	_	_	_
7	and	and	_	_	_	_	_	_	_
8	is	be	_	_	_	_	_	_	_
9	highly	highly	_	_	_	_	_	_	_
10	attenuated	attenuate	_	_	_	_	_	_	_
11	in	in	_	_	_	_	_	_	_
12	both	both	_	_	_	_	_	_	_
13	Jurkat	Jurkat	_	_	_	_	_	_	_
14	and	and	_	_	_	_	_	_	_
15	peripheral	peripheral	_	_	_	_	_	_	_
16	blood	blood	_	_	_	_	_	_	_
17	mononuclear	mononuclear	_	_	_	_	_	_	_
18	cells	cell	_	_	_	_	_	_	_
19	.	.	_	_	_	_	_	_	_

1	We	we	_	_	_	_	_	_	_
2	provide	provide	_	_	_	_	_	_	_
3	formal	formal	_	_	_	_	_	_	_
4	proof	proof	_	_	_	_	_	_	_
5	that	that	_	_	_	_	_	_	_
6	the	the	_	_	_	_	_	_	_
7	phenotypic	phenotypic	_	_	_	_	_	_	_
8	and	and	_	_	_	_	_	_	_
9	attenuating	attenuate	_	_	_	_	_	_	_
10	characteristics	characteristic	_	_	_	_	_	_	_
11	of	of	_	_	_	_	_	_	_
12	IkappaB-alphaS32/36A	IkappaB-alphaS32/36A	_	_	_	_	_	_	_
13	permit	permit	_	_	_	_	_	_	_
14	its	its	_	_	_	_	_	_	_
15	stable	stable	_	_	_	_	_	_	_
16	maintenance	maintenance	_	_	_	_	_	_	_
17	in	in	_	_	_	_	_	_	_
18	a	a	_	_	_	_	_	_	_
19	live	live	_	_	_	_	_	_	_
20	,	,	_	_	_	_	_	_	_
21	replicating	replicate	_	_	_	_	_	_	_
22	HIV-1	HIV-1	_	_	_	_	_	_	_
23	despite	despite	_	_	_	_	_	_	_
24	180	180	_	_	_	_	_	_	_
25	days	day	_	_	_	_	_	_	_
26	of	of	_	_	_	_	_	_	_
27	forced	force	_	_	_	_	_	_	_
28	ex	ex	_	_	_	_	_	_	_
29	vivo	vivo	_	_	_	_	_	_	_
30	passaging	passaging	_	_	_	_	_	_	_
31	in	in	_	_	_	_	_	_	_
32	tissue	tissue	_	_	_	_	_	_	_
33	culture	culture	_	_	_	_	_	_	_
34	.	.	_	_	_	_	_	_	_

1	As	as	_	_	_	_	_	_	_
2	compared	compare	_	_	_	_	_	_	_
3	with	with	_	_	_	_	_	_	_
4	other	other	_	_	_	_	_	_	_
5	open-reading	open-reading	_	_	_	_	_	_	_
6	frames	frame	_	_	_	_	_	_	_
7	embedded	embed	_	_	_	_	_	_	_
8	into	into	_	_	_	_	_	_	_
9	HIV/SIV	HIV/SIV	_	_	_	_	_	_	_
10	genome	genome	_	_	_	_	_	_	_
11	,	,	_	_	_	_	_	_	_
12	this	this	_	_	_	_	_	_	_
13	degree	degree	_	_	_	_	_	_	_
14	of	of	_	_	_	_	_	_	_
15	stability	stability	_	_	_	_	_	_	_
16	is	be	_	_	_	_	_	_	_
17	unprecedented	unprecedented	_	_	_	_	_	_	_
18	.	.	_	_	_	_	_	_	_

1	Thus	thus	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	IkappaB-alphaS32/36A	IkappaB-alphaS32/36A	_	_	_	_	_	_	_
4	offers	offer	_	_	_	_	_	_	_
5	proof-of-principle	proof-of-principle	_	_	_	_	_	_	_
6	that	that	_	_	_	_	_	_	_
7	artifactually	artifactually	_	_	_	_	_	_	_
8	gained	gain	_	_	_	_	_	_	_
9	functions	function	_	_	_	_	_	_	_
10	,	,	_	_	_	_	_	_	_
11	when	when	_	_	_	_	_	_	_
12	used	use	_	_	_	_	_	_	_
13	to	to	_	_	_	_	_	_	_
14	attenuate	attenuate	_	_	_	_	_	_	_
15	the	the	_	_	_	_	_	_	_
16	replication	replication	_	_	_	_	_	_	_
17	of	of	_	_	_	_	_	_	_
18	live	live	_	_	_	_	_	_	_
19	HIV-1	HIV-1	_	_	_	_	_	_	_
20	,	,	_	_	_	_	_	_	_
21	can	can	_	_	_	_	_	_	_
22	be	be	_	_	_	_	_	_	_
23	stable	stable	_	_	_	_	_	_	_
24	.	.	_	_	_	_	_	_	_

1	These	these	_	_	_	_	_	_	_
2	findings	finding	_	_	_	_	_	_	_
3	illustrate	illustrate	_	_	_	_	_	_	_
4	gain-of-function	gain-of-function	_	_	_	_	_	_	_
5	as	as	_	_	_	_	_	_	_
6	a	a	_	_	_	_	_	_	_
7	feasible	feasible	_	_	_	_	_	_	_
8	strategy	strategy	_	_	_	_	_	_	_
9	for	for	_	_	_	_	_	_	_
10	developing	develop	_	_	_	_	_	_	_
11	safer	safe	_	_	_	_	_	_	_
12	live-attenuated	live-attenuated	_	_	_	_	_	_	_
13	HIVs	hiv	_	_	_	_	_	_	_
14	to	to	_	_	_	_	_	_	_
15	be	be	_	_	_	_	_	_	_
16	tested	test	_	_	_	_	_	_	_
17	as	as	_	_	_	_	_	_	_
18	candidates	candidate	_	_	_	_	_	_	_
19	for	for	_	_	_	_	_	_	_
20	AIDS	AIDS	_	_	_	_	_	_	_
21	vaccine	vaccine	_	_	_	_	_	_	_
22	.	.	_	_	_	_	_	_	_

